Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir

Author： Bongiovanni M.   Chiesa E.   Riva A.   d'Arminio Monforte A.   Bini T.  

Publisher： Elsevier

ISSN： 0924-8579

Source： International Journal of Antimicrobial Agents, Vol.22, Iss.6, 2003-12, pp. : 630-631

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

By Barragan Patricia   Podzamczer Daniel  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 13, 2008-09 ,pp. : 2363-2375

Informa Healthcare

Access to resources Recommend Favorite

Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite

Lopinavir/Ritonavir: A Review of its Use in the Management of HIV-1 Infection

By Croxtall Jamie D.   Perry Caroline M.  

Drugs, Vol. 70, Iss. 14, 2010-10 ,pp. : 1885-1915

Adis International

Access to resources Recommend Favorite

Darunavir + ritonavir superior to lopinavir/ritonavir for HIV infection

By  

Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Long-term lopinavir/ritonavir effective in HIV infection

By  

Inpharma, Vol. 1, Iss. 1435, 2004-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite